Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial

Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β(2)-agonist (LABA)), glycopyrronium bromide (GLY, long-acting muscarinic antagonist) and mometasone furoate...

詳細記述

保存先:
書誌詳細
出版年:ERJ Open Res
主要な著者: Beier, Jutta, Watz, Henrik, Diamant, Zuzana, Hohlfeld, Jens M., Singh, Dave, Pinot, Pascale, Jones, Ieuan, Tillmann, Hanns-Christian
フォーマット: Artigo
言語:Inglês
出版事項: European Respiratory Society 2021
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053816/
https://ncbi.nlm.nih.gov/pubmed/33898609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00425-2020
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料